Precigen Inc (PGEN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.78 (-1.14%), Market cap $1.52B, 52-week low–high $1.32 ~ $5.21.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary periton
Financial statements, price targets, institutional (13F) holdings and related news for Precigen Inc are updated in real time on BlackAll Trade.
Precigen Inc trades at $7.78 (-1.14%). Real-time quotes and charts are available on BlackAll Trade.
Precigen Inc has a market cap of about $1.52B.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorder